Medical Literature Service Just Published Available on MSD's Leading Medical Education and Information Website
WHITEHOUSE STATION, N.J. -- (BUSINESS WIRE) --
MSD (known as Merck in the United States and Canada) is pleased to announce an exciting and exclusive new partnership between univadis® - (MSD's medical education and unbiased health information website) and The Lancet - (one of the world's leading independent general medical journals). Through a unique global medical literature service called Just Published, clinical specialists registered on univadis® will receive free access to the full text of recently published articles from The Lancet. This new service will be available on www.univadis.com.
Just Published aims to help clinicians keep abreast of the latest and most important clinical information in their field by providing the full text of key research articles recently published in The Lancet, and weekly summaries of research in other top journals. To ensure full independence and impartiality of Just Published and delivery of the most relevant information, articles from other top journals will be identified and selected on the basis of elements such as journal impact factors, author citations, and article downloads.
"With the enormous variety of medical content now available online, never has it been more important for healthcare professionals to have timely access to trustworthy and unbiased health information. We are delighted to be partnering with The Lancet to further enhance the univadis® website bringing comprehensive independent medical information to physicians worldwide. Providing high quality services to physicians, such as univadis®, and ultimately improving patient outcomes is a core part of our corporate strategy, dating back to the first published Merck Manual more than 100 years ago," said Fabrice Valay, head of univadis® at MSD.
Abstracts of articles from The Lancet and summaries of articles from other journals will initially be offered in English, French, German, Italian, Spanish, Brazilian Portuguese, and Japanese to serve the dozens of countries around the world in which univadis® is available.
About The Lancet
Founded in 1823 by surgeon Thomas Wakley with a vision 'to inform, to reform, and to entertain', nearly 200 years later The Lancet's vision remains unchanged. This weekly journal seeks to influence clinical practice through the publication of high-quality peer-reviewed research covering a broad spectrum of medical disciplines of appeal to clinical practitioners in general medicine and research academics around the globe.
Publishing groundbreaking discoveries that serve to reform and inform medical thought and innovation is a hallmark of The Lancet's long history. The Lancet has published pioneering medical research such as Lister's antiseptic principle, the value of penicillin, HIV transmission, the Hepatitis C virus, and in-vitro fertilization.
From its very first issue on October 5, 1823, The Lancet has been, first and foremost, a reformist medical newspaper. Thomas Wakley and his successors have aimed to combine publication of the best medical science in the world with a zeal to counter the forces that undermine the value of medicine, be they political, social, or commercial.
In addition to the publication of peer-reviewed research, the journal keeps readers worldwide up-to-date with the latest news in science and medicine, and educates readers through a weekly seminar on a specific topic and regular review articles analysing the status of research in a particular field.
Three monthly specialty journals - THE LANCET Oncology, THE LANCET Infectious Diseases, and THE LANCET Neurology - are also available.
About Elsevier, publisher of The Lancet
Elsevier is a world-leading publisher of scientific, technical, and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet (www.thelancet.com) and Cell (www.cell.com), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect (www.sciencedirect.com), Scopus (www.scopus.com), Reaxys (www.reaxys.com), MD Consult (www.mdconsult.com), and Nursing Consult (www.nursingconsult.com), which enhance the productivity of science and health professionals, and the SciVal suite (www.scival.com) and MEDai's Pinpoint Review (www.medai.com), which help research and healthcare institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier (www.elsevier.com) employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC (www.reedelsevier.com), a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK, and ENL (New York Stock Exchange).
About univadis®
univadis® is a leading medical education and information website provided by MSD (known as Merck in the U.S. and Canada) offering high quality, independent and trusted medical content. It is a leading portal for healthcare professionals giving fast and easy free access to a range of educational content and valuable medical support services with the ultimate goal of improving the patient outcome. MSD has been providing information to healthcare professionals for over 100 years through the MSD Manual (also known as Merck Manual) and is one of the most trusted sources of medical knowledge worldwide.
With an easy-to-use interface, univadis® features breaking medical news, 400+ peer reviewed online education courses, 3D anatomy, 3,000+ medical images and cutting-edge tools specifically tailored to the needs of healthcare professionals medical specialty. univadis® is available in 20+ languages in 36 countries worldwide and currently has 850,000 registered users.
About MSD
Today's MSD is a global healthcare leader working to help the world be well. MSD is a tradename of Merck & Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.msd.com.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6491172&lang=en
CONTACT:
MSD
Monique Mols, +31 (0)412 66 5440
or
Lancet Press Office
pressoffice@lancet.com